| Cash Flow | 2025-06-30 |
|---|---|
| Stock-based compensation | 4,550 |
| Net loss | -20,102 |
| Prepaid expenses and other current assets | 105 |
| Other long-term assets | 7 |
| Accrued expenses and other current liabilities | -1,596 |
| Accounts payable | 30 |
| Depreciation and amortization | 135 |
| Amortization of debt discount and other non-cash interest | 359 |
| Non-cash operating lease cost | 184 |
| Lease liabilities and other long-term liabilities | -180 |
| Loss (gain) on fair value remeasurement of contingent consideration | -174 |
| Net cash used in operating activities | -16,558 |
| Purchases of property and equipment and other assets | 16 |
| Net cash used in investing activities | -16 |
| Proceeds from issuance of common stock under employee stock purchase plan | 13 |
| Payment of principal on finance lease | 58 |
| Payment of issuance costs from issuance of common and preferred stock | 120 |
| Payment of principal, prepayment premium and payment fee on debt | 2,500 |
| Net cash provided by financing activities | -2,665 |
| Net decrease in cash and cash equivalents | -19,239 |
KALA BIO, Inc. (KALA)
KALA BIO, Inc. (KALA)